查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1830063

疫苗開發企業的形勢:競爭情形，最近的事業擴大，聯盟·共同研究，大型製藥企業的配合措施，成本價格分析

Vaccine Development Companies Landscape: Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
出版日期: | 出版商: Roots Analysis | 英文 86 Pages | 商品交期: 最快1-2個工作天內

價格

新興疫苗市場：概述

預計2024年，全球疫苗研發企業將生產約70億劑疫苗，2025年將生產約80億劑。

疫苗研發市場：成長與趨勢

疫苗是一種專門配製的醫療產品，旨在刺激人體免疫系統識別並長期抵抗特定疾病。疫苗研發通常涉及使用減毒或滅活的致病微生物，或包含病原體的關鍵抗原成分，例如結構蛋白或滅活毒素。 透過引入這些成分，疫苗可以幫助免疫系統在未來再次遇到病原體時識別並對抗它。

根據世界衛生組織（WHO）的定義，疫苗分為兩類：預防性疫苗用於保護個人免受疾病感染，而治療性疫苗則用作治療方案，幫助人體對抗現有疾病。製藥公司目前提供多種疫苗，其中許多疫苗正處於臨床試驗或不同的研發階段，針對各種嚴重且致殘性疾病。

最近，流行病防範創新聯盟（CEPI）向疫苗和傳染病組織（VIDO）追加了2400萬美元的巨額投資，以加強全球應對未來傳染病疫情的準備工作，因為世界仍在與最新的大流行病作鬥爭。

疫苗研發者開發和批准的創新疫苗，包括mRNA疫苗、DNA疫苗和重組疫苗，正在顯著影響疫苗市場的競爭格局。

新興疫苗市場：關鍵洞察

本報告分析了疫苗研發市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

  • 當前市場格局高度分散，既有新進者，也有成熟企業。其中，近25%的疫苗研發公司屬於大型或超大型企業。
疫苗研發公司格局：競爭格局、近期擴張、合作與夥伴關係、大型製藥公司舉措及成本價格分析
  • 35%的疫苗正處於不同階段的臨床試驗中，超過40%的疫苗處於探索性/臨床前階段。
  • 大多數擴張計劃都已在過去幾年中實施，其中近 55% 的計劃側重於加強現有疫苗研發​​能力，以滿足不斷增長的需求。
  • 近期的大部分擴張（約 40%）都發生在亞太地區的設施中，其中印度和新加坡是擴張規模最大的地區。
Vaccine Development Companies Landscape:Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
  • 到 2024 年，近 50% 的疫苗相關合作將達成，其中超過 15% 為生產和產品開發協議。
Vaccine Development Companies Landscape:Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
  • 超過45%的大型製藥公司已達成各種合作關係，以加強其現有的疫苗產品組合，其次是擁有多項擴張計劃的公司（43%）。

新興國家疫苗研發市場：主要細分市場

疫苗研發公司的競爭格局

目前市場格局包含200多家疫苗​​研發公司，其中包括超大型、大型、中型和小型公司。

這些疫苗研發公司擁有在各個關鍵地區開發各類疫苗所需的專業知識，包括癌症疫苗、mRNA疫苗、呼吸道合胞病毒（RSV）疫苗和DNA疫苗。值得注意的是，大多數公司總部位於北美，其次是亞太地區。近期成立的知名疫苗研發公司（按字母順序排列，成立於2020年後）包括AbVacc、Auro Vaccines、HilleVax、Innovac Therapeutics、Nuravax、Pyrojas和Vernagen。

近年來，疫苗研發市場的合作活動日益活躍。尤其是在過去五年中，北美和歐洲的公司建立了大多數聯盟，以促進疫苗研發進程。該領域的大多數合作是生產協議，其次是產品開發協議。這反映了疫苗研發公司為推動各類疫苗的研發活動所做的不懈努力。

近期工廠擴建提升產能

疫苗研發企業正在進行大規模的工廠擴建，以滿足日益增長的全球需求並提升生產能力。 2025年3月，默克公司在北卡羅來納州開設了一座價值10億美元的現代化疫苗生產工廠，該工廠採用了人工智慧和3D列印等尖端技術。其他主要公司，包括龍沙和藥明生物，也在全球擴大了正在研發的新型mRNA疫苗和病毒載體疫苗的生產能力。這些投資凸顯了該行業致力於提高產量、促進創新和加強供應鏈以滿足未來疫苗需求的決心。

疫苗研發公司範例

  • AstraZeneca
  • CSL
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • Takeda

疫苗開發企業的形勢:調查對象

  • 市場概況：基於以下幾個相關參數，對疫苗研發市場中的公司進行詳細評估：A) 成立年份，B) 公司規模，C) 總部所在地，D) 疫苗用途，E) 疫苗類型，F) 亞單位疫苗類型，G) 治療領域，H) 目標傳染病類型。
  • 近期業務擴張：A) 擴張年份，B) 擴張類型，C) 擴張設施位置，D) 擴張設施面積，E) 投資金額，F) 擴張目的。
  • 合作夥伴關係與合作：基於以下參數，對該領域報告的合作夥伴關係活動進行深入分析：A) 合作年份，B) 合作類型，C) 合作夥伴類型，D) 疫苗類型，E) 治療領域，以及 F) 地理分佈。
  • 大型製藥公司措施：基於以下參數，對該領域報告的大型製藥公司舉措進行深入分析：A) 舉措年份，B) 合作類型，C) 擴張類型，以及 F) 疫苗重點類型。
  • 成本價格分析：A] 疫苗生產成本的主要歷史趨勢，[B] 疫苗成本結構，[C] 影響疫苗定價的因素，[D] 與疫苗生產相關的投資考慮因素，以及 [E] 疫苗研發和生產過程中的成本降低策略。

目錄

第1章 背景

第2章 調查手法

第3章 市場動態

  • 章節概要
  • 預測調查手法
  • 市場評估組成架構
  • 預測工具和技巧
  • 重要的考慮事項
  • 限制事項

第4章 宏觀經濟指標

  • 章節概要
  • 市場動態
  • 結論

第5章 摘要整理

第6章 簡介

  • 疫苗概要
  • 疫苗的種類
  • 疫苗的優點
  • 疫苗相關的課題
  • 未來展望

第7章 市場形勢

  • 章節概要與研究方法
  • 關鍵參數
  • 疫苗研發企業：市場概況

第8章 最近的事業擴大

  • 章節概要
  • 擴張模式
  • 疫苗開發商:最近的事業擴大

第9章 夥伴關係和合作

  • 章節概要
  • 夥伴關係模式
  • 疫苗開發商:夥伴關係和合作

第10章 大型製藥公司的配合措施

  • 章節概要與調查手法
  • 與主要的配合措施評價標準
  • 大型製藥公司:疫苗相關的配合措施

第11章 原價分析

  • 成本與價格分析概要
  • 疫苗製造成本的主要的歷史趨勢
  • 疫苗的成本結構
  • 疫苗價格的影響因素
  • 疫苗生產相關的投資的考慮事項
  • 降低成本分析
  • 疫苗開發·製造流程的降低成本策略

第12章 附錄I:表格形式資料

第13章 附錄II:企業及組織一覽

Product Code: RA100620

Vaccine Developers Market: Overview

The vaccine development companies produced an estimated 7 billion doses of vaccines globally, in the year 2024 and are expected to produce around 8 billion doses in 2025.

Vaccine Developers Market: Growth and Trends

Vaccine is a specialized medical product formulated to activate the body's immune system, enabling it to recognize and protect against specific diseases over the long term. The development of vaccines typically involves using either weakened or inactivated forms of the disease-causing microorganism, or including crucial antigenic components from the pathogen, such as structural proteins and inactivated toxins. By introducing these components, vaccines assist the immune system in recognizing and combating the real pathogen if encountered in the future.

According to World Health Organization, vaccines are categorized into two types, namely preventive (prophylactic) vaccines, which are administered to protect individuals from contracting diseases, and therapeutic vaccines, which are utilized as treatment regimens to help the body fight existing illnesses. Currently, pharmaceutical companies offer numerous vaccines, and many are undergoing clinical trials or are in various stages of development, targeting a wide range of serious and debilitating conditions.

Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) has made a significant new investment of USD 24 million in the Vaccine and Infectious Disease Organization (VIDO), aiming to bolster global preparedness for future infectious disease outbreaks as the world continues to combat the last pandemic.

Significantly, the development and approval of innovative vaccines, by vaccine development companies, such as mRNA, DNA, and recombinant vaccines, are significant trends influencing the competitive landscape of vaccines market.

Vaccine Developers Market: Key Insights

The report delves into the current state of the vaccine developers market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • The current market landscape is highly fragmented, featuring the presence of both new entrants and established players; of these, close to 25% of the vaccine developers are large and very large players.
Vaccine Development Companies Landscape: Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
  • 35% vaccines are being evaluated across different phases of clinical trials; notably, more than 40% of the vaccines are under discovery / preclinical stage.
  • Most of the expansion initiatives were undertaken in the past few years; of these, nearly 55% of the instances were focused on enhancing the existing vaccine development capabilities to meet increasing demand.
  • Majority of the recent expansions (~40%) were undertaken in facilities located in Asia-Pacific; notably, India and Singapore emerged as the key regions where most of the expansions were undertaken.
Vaccine Development Companies Landscape: Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
  • Close to 50% of the vaccines-related partnerships were inked in the year 2024; of these, more than 15% of the agreements were manufacturing and product development agreements.
Vaccine Development Companies Landscape: Competitive Landscape, Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis
  • Over 45% of the big pharma players have signed various partnerships to enhance their existing vaccine portfolios, followed by players (43%) undertaking several expansion initiatives.

Vaccine Developers Market: Key Segments

Competitive Landscape of Vaccine Development Companies

The current market landscape takes into account more than 200 vaccine developers including very large, large, mid-sized and small companies. These vaccine developers have the required expertise to develop different types of vaccines, such as cancer vaccines, mRNA vaccines, RSV vaccines and DNA vaccine across different key geographical regions. Notably, most companies are based in North America, followed by Asia-Pacific; this is reflective of the high market potential in these regions. Notable examples of recently established vaccine developers (established post-2020, in alphabetical order) include AbVacc, Auro Vaccines, HilleVax, Innovac Therapeutics, Nuravax, Pyrojas and Vernagen.

Rising Partnerships and Collaborations Activity to Foster Progress and Innovation in Expanding their Capabilities

The vaccine development market has witnessed a decent partnership activity in the past few years. Notably, in the last five years, companies based in North America and Europe have inked majority of the partnerships to strengthen their development processes of vaccines. Most of the partnerships signed in this domain are manufacturing agreements, followed by product development agreements. This is indicative of the persistent efforts of vaccine developers to advance their research and development activities for the development of different types of vaccines.

Recent Facility Expansions to Improve Capacity

The vaccine development players have witnessed significant facility expansions to meet growing global demand and advance manufacturing capabilities. In March 2025, Merck opened a USD 1 billion state-of-the-art vaccine manufacturing plant in North Carolina, incorporating cutting-edge technologies, such as AI and 3D printing. Other key players, including Lonza and WuXi Biologics, have also expanded their new mRNA vaccines in development and viral vector vaccine capacities worldwide. These investments emphasize the sector's commitment to increasing production, boosting innovation, and reinforcing supply chains to fulfill future vaccine needs.

Example Players in the Vaccine Development Companies Landscape

  • AstraZeneca
  • CSL
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • Takeda

Vaccine Development Companies Landscape: Research Coverage

  • Market Landscape: An in-depth assessment of the companies involved in the vaccine development market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] purpose of vaccine, [E] type of vaccine [F] type of subunit vaccine, [G] therapeutic area, and [H] type of infectious diseases targeted.
  • Recent Expansions: A detailed analysis of the expansion initiatives undertaken in the vaccine development domain, on the basis of [A] year of expansion, [B] type of expansion, [C] location of expanded facility, [D] area of expanded facility, [E] amount invested and [F] purpose of expansion.
  • Partnerships and Collaborations: An in-depth analysis of the partnership's activity reported in this domain, based on parameters such as [A] year of partnership, [B] type of partnership [C] type of partner, [D] type of vaccine, [D] therapeutic area and [E] geographical distribution.
  • Big Pharma Initiatives: A detailed analysis of big pharma initiatives reported in the domain, on the basis of [A] year of initiative, [B] type of partnership, [C] type of expansion, and [D] type of vaccine focused.
  • Cost Price Analysis: An in-depth cost price analysis depicting [A] key historical trends in vaccine production costs, [B] vaccine cost structure, [C] factors influencing vaccine prices, [D] investment considerations associated with vaccines production and [E] cost-saving strategies in vaccine development and manufacturing processes.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product (GDP)
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross-Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. An Overview of Vaccines
  • 6.2. Types of Vaccines
  • 6.3. Advantages of Vaccines
  • 6.4. Challenges Associated with Vaccines
  • 6.5. Future Perspectives

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview and Methodology
  • 7.2. Key Parameters
  • 7.3. Vaccine Developers: Overall Market Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Stage of Development
    • 7.3.4. Analysis by Location of Headquarters
    • 7.3.5. Analysis by Company Size and Location of Headquarters
    • 7.3.6. Analysis by Purpose of Vaccine
    • 7.3.7. Analysis by Type of Vaccine
    • 7.3.8. Analysis by Type of Subunit Vaccine
    • 7.3.9. Analysis by Therapeutic Area
    • 7.3.10. Analysis by Type of Infectious Diseases Targeted

8. RECENT EXPANSIONS

  • 8.1. Chapter Overview
  • 8.2. Expansion Models
  • 8.3. Vaccine Developers: Recent Expansions
    • 8.3.1. Analysis by Year of Expansion
    • 8.3.2. Analysis by Type of Expansion
    • 8.3.3. Analysis by Year and Type of Expansion
    • 8.3.4. Analysis by Location of Expanded Facility
    • 8.3.5. Analysis by Area of Expanded Facility
    • 8.3.6. Analysis by Type of Expansion and Location of Expanded Facility
    • 8.3.7. Analysis by Amount Invested
    • 8.3.8. Analysis by Type of Expansion and Amount Invested
    • 8.3.9. Analysis by Purpose of Expansion
      • 8.3.9.1. Most Active Players: Analysis by Number of Initiative
      • 8.3.9.2. Most Active Players: Analysis by Amount Invested

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Vaccine Developers: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Type of Vaccine
    • 9.3.6. Analysis by Therapeutic Area
    • 9.3.7. Most Active Players: Analysis by Number of Partnerships
    • 9.3.8. Analysis by Geography
      • 9.3.8.1. Local and International Agreements
      • 9.3.8.2. Intracontinental and Intercontinental Agreements

10. BIG PHARMA INITIATIVES

  • 10.1. Chapter Overview and Methodology
  • 10.2. Key Initiatives and Scoring Criteria
  • 10.3. Big Pharma Players: Vaccine-related Initiatives
    • 10.3.1. Analysis of Big Pharma Players by Number of Initiatives
    • 10.3.2. Analysis by Year of Initiative
    • 10.3.3. Analysis of Big Pharma Players by Year and Number of Initiatives
    • 10.3.4. Analysis by Type of Initiative
    • 10.3.5. Analysis by Year and Type of Initiative
    • 10.3.6. Analysis by Type of Partnership
    • 10.3.7. Analysis by Type of Expansion
    • 10.3.8. Analysis by Type of Vaccine Focused
    • 10.3.9. Benchmarking of Initiatives by Big Pharma Players: Spider Web Analysis

11. COST PRICE ANALYSIS

  • 11.1. An Overview of Cost and Price Analysis
  • 11.2. Key Historical Trends in Vaccine Production Costs
  • 11.3. Vaccine Cost Structure
  • 11.4. Factors Influencing Vaccine Prices
  • 11.5. Investment Considerations Associated with Vaccines Production
  • 11.6. Cost Saving Analysis
    • 11.6.1. Key Components of Cost Saving Analysis
    • 11.6.2. Benefits of Cost Saving Analysis
  • 11.7. Cost-Saving Strategies in Vaccine Development and Manufacturing Processes
    • 11.7.1. Developers Optimizing R&D and Delivery Systems
    • 11.7.2. Manufacturers Adopting Cost-Saving Measures

12. APPENDIX I: TABULATED DATA

13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 Vaccine Developers Market: Vaccine Developers
  • Table 8.1 Vaccine Developers Market: Recent Expansions
  • Table 9.1 Vaccine Developers Market: Partnerships and Collaborations
  • Table 10.1 Big Pharma Players: Vaccine -related Initiatives, since 2023
  • Table 12.1 Vaccine Developers: Distribution by Year of Establishment
  • Table 12.2 Vaccine Developers: Distribution by Company Size
  • Table 12.3 Vaccine Developers: Distribution by Stage of Development
  • Table 12.4 Vaccine Developers: Distribution by Year of Establishment
  • Table 12.5 Vaccine Developers: Distribution by Location of Headquarters
  • Table 12.6 Vaccine Developers: Company Size and Location of Headquarters
  • Table 12.7 Vaccine Developers: Distribution by Purpose of Vaccine
  • Table 12.8 Vaccine Developers: Distribution by Type of Vaccine
  • Table 12.9 Vaccine Developers: Distribution by Type of Subunit Vaccine
  • Table 12.10 Vaccine Developers: Distribution by Type of Infectious Diseases Targeted
  • Table 12.11 Recent Expansions: Distribution by Year of Expansion, Since 2020
  • Table 12.12 Recent Expansions: Distribution by Type of Expansion
  • Table 12.13 Recent Expansions: Distribution by Year and Type of Expansion, Since 2020
  • Table 12.14 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 12.15 Recent Expansions: Distribution by Area of Expanded Facility
  • Table 12.16 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
  • Table 12.17 Recent Expansions: Distribution by Amount Invested
  • Table 12.18 Recent Expansions: Distribution by Type of Expansion and Amount Invested
  • Table 12.19 Recent Expansions: Distribution by Purpose of Expansion
  • Table 12.20 Most Active Players: Distribution by Distribution by Number of Initiatives
  • Table 12.21 Most Active Players: Distribution by Distribution by Amount Invested
  • Table 12.22 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2023
  • Table 12.23 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2023
  • Table 12.25 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 12.26 Partnerships and Collaborations: Distribution by Type of Vaccine
  • Table 12.27 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 12.28 Most Active Players: Distribution by Distribution by Number of Partnerships
  • Table 12.29 Partnerships and Collaborations: Distribution by Local and International Agreements
  • Table 12.30 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
  • Table 12.31 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Table 12.32 Big Pharma Initiatives: Distribution by Year of Initiative, Since 2023
  • Table 12.33 Big Pharma Initiatives: Distribution by Year and Number of Initiative, Since 2023
  • Table 12.34 Big Pharma Initiatives: Distribution by Type of Initiative
  • Table 12.35 Big Pharma Initiatives: Distribution by Year and Type of Initiative, Since 2023
  • Table 12.36 Big Pharma Initiatives: Distribution by Type of Partnership
  • Table 12.37 Big Pharma Initiatives: Distribution by Type of Expansion
  • Table 12.38 Big Pharma Initiatives: Distribution by Type of Vaccine Focused

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
  • Figure 5.1 Executive Summary: Overall Vaccine Developers Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 6.1 Types of Vaccines
  • Figure 6.2 Advantages of Vaccines
  • Figure 6.3 Challenges Associated with Vaccines
  • Figure 6.4 Future Perspectives
  • Figure 7.1 Vaccine Developers: Distribution by Year of Establishment
  • Figure 7.2 Vaccine Developers: Distribution by Company Size
  • Figure 7.3 Vaccine Developers: Distribution by Stage of Development
  • Figure 7.4 Vaccine Developers: Distribution by Year of Establishment
  • Figure 7.5 Vaccine Developers: Distribution by Location of Headquarters
  • Figure 7.6 Vaccine Developers: Company Size and Location of Headquarters
  • Figure 7.7 Vaccine Developers: Distribution by Purpose of Vaccine
  • Figure 7.8 Vaccine Developers: Distribution by Type of Vaccine
  • Figure 7.9 Vaccine Developers: Distribution by Type of Subunit Vaccine
  • Figure 7.10 Vaccine Developers: Distribution by Type of Infectious Diseases Targeted
  • Figure 8.1 Recent Expansions: Distribution by Year of Expansion, Since 2020
  • Figure 8.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 8.3 Recent Expansions: Distribution by Year and Type of Expansion, Since 2020
  • Figure 8.4 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 8.5 Recent Expansions: Distribution by Area of Expanded Facility
  • Figure 8.6 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
  • Figure 8.7 Recent Expansions: Distribution by Amount Invested
  • Figure 8.8 Recent Expansions: Distribution by Type of Expansion and Amount Invested
  • Figure 8.9 Recent Expansions: Distribution by Purpose of Expansion
  • Figure 8.10 Most Active Players: Distribution by Distribution by Number of Initiatives
  • Figure 8.11 Most Active Players: Distribution by Distribution by Amount Invested
  • Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2023
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2023
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Vaccine
  • Figure 9.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 9.7 Most Active Players: Distribution by Distribution by Number of Partnerships
  • Figure 9.8 Partnerships and Collaborations: Distribution by Local and International Agreements
  • Figure 9.9 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
  • Figure 10.1 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Figure 10.2 Big Pharma Initiatives: Distribution by Year of Initiative, Since 2023
  • Figure 10.3 Big Pharma Initiatives: Distribution by Year and Number of Initiative, Since 2023
  • Figure 10.4 Big Pharma Initiatives: Distribution by Type of Initiative
  • Figure 10.5 Big Pharma Initiatives: Distribution by Year and Type of Initiative, Since 2023
  • Figure 10.6 Big Pharma Initiatives: Distribution by Type of Partnership
  • Figure 10.7 Big Pharma Initiatives: Distribution by Type of Expansion
  • Figure 10.8 Big Pharma Initiatives: Distribution by Type of Vaccine Focused
  • Figure 10.9 Benchmarking of Initiatives of Big Pharma Players: Spider Web Analysis
  • Figure 11.1 Cost Price Analysis: Key Historical Trends in Vaccine Production Costs
  • Figure 11.2 Cost Price Analysis: Vaccine Cost Structure
  • Figure 11.3 Cost Price Analysis: Factors Influencing Vaccine Prices
  • Figure 11.4 Cost Price Analysis: Investment Considerations Associated with Vaccines Production
  • Figure 11.5 Cost Price Analysis: Key Components of Cost Saving Analysis
  • Figure 11.6 Cost Price Analysis: Benefits of Cost Saving Analysis
  • Figure 11.7 Cost Price Analysis: Developers Optimizing R&D and Delivery Systems
  • Figure 11.8 Cost Price Analysis: Manufacturers Adopting Cost-Saving Measures